Companies like Enveric Biosciences are taking a different approach by attempting to strip psychedelics of their hallucinogenic effects altogether. Enveric’s CEO Joseph Tucker suggests that a non-hallucinogenic version of psychedelics, if effective, could function much like an antidepressant, providing relief without the need for extensive in-clinic sessions.
